DOCUMENT
supplementary figure 1.pdf (50.58 kB)
DOCUMENT
supplementary figure 2.pdf (10 kB)
1/0
Supplementary Figures – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
figure
posted on 2021-11-11, 10:00 authored by Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke|
Supplementary Figure 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status CONSORT diagram of patient selection. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PS, performance status
Supplementary Figure 2. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status The changes in ECOG-PS score due to treatment with osimertinib. The blue, black, and red line indicates the patients whose baseline of PS was 4, 3, and 2, respectively. ECOG-PS, Eastern Cooperative Oncology Group-performance status |
